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Abstract
Background:  Detection of circulating malignant cells (CMCs) through a reverse transcriptase-
polymerase chain reaction (RT-PCR) assay seems to be a demonstration of systemic disease. We here
evaluated the prognostic role of RT-PCR assays in serially-taken peripheral blood samples from patients
with malignant melanoma (MM).
Methods: One hundred forty-nine melanoma patients with disease stage ranging from I to III were
consecutively collected in 1997. A multi-marker RT-PCR assay was used on peripheral blood samples
obtained at time of diagnosis and every 6 months during the first two years of follow-up (total: 5 samples).
Univariate and multivariate analyses were performed after 83 months of median follow-up.
Results: Detection of at least one circulating mRNA marker was considered a signal of the presence of
CMC (referred to as PCR-positive assay). A significant correlation was found between the rate of
recurrences and the increasing number of PCR-positive assays (P = 0.007). Presence of CMC in a high
number (≥2) of analysed blood samples was significantly correlated with a poor clinical outcome (disease-
free survival: P = 0.019; overall survival: P = 0.034). Multivariate analysis revealed that presence of a PCR-
positive status does play a role as independent prognostic factors for overall survival in melanoma patients,
adding precision to the predictive power of the disease stage.
Conclusion: Our findings indicated that serial RT-PCR assay may identify a high risk subset of melanoma
patients with occult cancer cells constantly detected in blood circulation. Prolonged presence of CMCs
seems to act as a surrogate marker of disease progression or a sign of more aggressive disease.
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Background
The poor prognosis of patients with malignant melanoma
(MM) is mostly due to the high frequency of distant dis-
semination of the disease. Considering the small size of
most primary melanomas, the metastatic potential of MM
is considerably greater than that of most other solid
tumours [1].
The relationship between presence of circulating cancer
cells and development of secondary disease is not fully
understood. Detection of circulating malignant cells
(CMCs) is actually aimed to the identification of either an
earlier marker of tumour progression or a phenotypic fea-
ture of more aggressive disease that might change treat-
ment options [2]. Detection of CMCs in peripheral blood
of MM patients at early-stage disease could indicate a sys-
temic dissemination of the tumour cells and, thus, a
higher risk of developing metastasis [3].
Reverse transcriptase-polymerase chain reaction (RT-PCR)
can detect a single specific messenger RNA (mRNA) in a
mixed cell population; thus, it can be a sensitive method
for identification of circulating tumour cells [4-7]. Tyrosi-
nase (TYR), an enzyme that is involved in the melanin
biosynthesis pathway [8], is the marker most frequently
used to detect the presence of CMC in melanoma patients;
however, its clinical usefulness is highly debated [9-13].
To improve sensitivity and specificity of the procedure, we
and others have previously proposed a multi-marker RT-
PCR assay, including melanA/MART1 in addition to tyro-
sinase (the use of TYR mRNA as unique marker could be
of limited value in the management of MM patients, due
to the heterogeneity of TYR expression in melanomas)
[14-18]. Such a multi-marker RT-PCR assay has been dem-
onstrated to really improve the detection of melanoma-
associated transcripts in peripheral blood of patients who
have undergone radical surgery [7,14,15]. Detection of
minimal residual disease at the time of diagnosis by RT-
PCR seems to be correlated with the initial clinical stage;
however, our group has demonstrated that it does not add
any power to the predictive value of the disease stage [19].
We here investigated whether serial detection of circulat-
ing melanoma-associated markers by performing consec-
utive multi-marker RT-PCR assays on peripheral blood
samples obtained during patients' follow-up may
improve prognostic prediction, commonly based on path-
ological and clinical factors. Moreover, the current study
was designed to examine the impact of longer duration of
follow-up on the prognostic relevance of such a molecular
assay in the assessment of clinical outcome among
melanoma patients.
Methods
Sample collection
The study was conducted with patients referring to the
National Cancer Institute of Naples between January 9,
1997 and December 16, 1997. Patients were consecutively
collected and considered eligible if they had a histological
diagnosis of cutaneous malignant melanoma (performed
either inside or outside the Institute; in the latter case,
slides were reviewed by internal pathologists). Eight out
of 157 enrolled patients were excluded from the series
since they were early lost in follow-up (in a period ranging
from 9 to 14 months).
For the 149 patients included into the study, clinical stage
was documented at the time of enrollment and prospec-
tively followed-up. Patients with no clinical evidence of
regional or metastatic disease underwent the sentinel
lymph node (SLN) dissection. Histopathologic examina-
tion was performed on each formalin-fixed paraffin-
embedded SLN using hematoxylin/eosin staining and
immunohistochemistry (IHC) of adjacent sections. For
IHC, 4-µm-thick sections were evaluated by using anti-
bodies against HMB-45 and S-100 proteins. All stage III
patients received the same adjuvant therapy with low dose
interferon alpha (as we previously described [20]). Dis-
ease stage has been codified by clinicians in charge of the
patients, according to the recent American Joint Commit-
tee on Cancer (AJCC) guidelines [21].
For collection of baseline peripheral blood samples (time
0; sample 1), patients (stage I to III) were eligible if no
more than two weeks had elapsed from the surgical treat-
ment. All patients were visited every six months after the
diagnosis. During the first two years of follow-up, periph-
eral blood samples were taken at 6, 12, 18, and 24 months
after diagnosis (times 1, 2, 3, and 4; samples 2, 3, 4, and
5; respectively) and addressed to the RT-PCR screening.
Death before the third blood sample (within 12 months
after diagnosis) was an exclusion criterion; no patients
was excluded for such a criterion. No clinical decision was
made based on the result of the RT-PCR assay.
At each follow-up time, a clinical history, physical exami-
nation, cell blood count, and blood biochemistry were
performed. Instrumental assessments were performed if
clinically indicated. Patients were informed about aims
and limits of the study; peripheral blood samples for RT-
PCR analysis were obtained with their written consent.
The study was reviewed and approved by the ethical
review boards of both the National Tumor Institute of
Naples and the University of Sassari.
Sample Preparation and RT-PCR assay
Nucleated cells from peripheral blood were processed in
order to isolate total RNA, using standard procedures.BMC Cancer 2006, 6:266 http://www.biomedcentral.com/1471-2407/6/266
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In our previous report, a multiple-marker RT-PCR assay
(including tyrosinase, p97, and MelanA/MART1 markers)
was tested for its sensitivity and specificity in detecting cir-
culating melanoma-associated mRNAs [15]. Analysis of
total cellular RNA obtained from peripheral blood of 235
patients with either localized or metastatic MM as well as
of 41 negative controls (20 healthy subjects and 21
patients with different types of cancer) demonstrated that
maximal values of sensitivity and specificity were reached
by tyrosinase and MelanA/MART1 [15]. In the present
study, we therefore decided to use such two markers
(primer sequences and protocols for RT-PCR assay were as
previously described [15]).
Integrity of RNA was determined by performing parallel
RT-PCR reaction using primers specific for the housekeep-
ing gene GAPDH [15]. Samples that failed to amplify
products for GAPDH RNA were considered non-informa-
tive and discarded. In each RT-PCR assay, final products
were separated by electrophoresis on 2% agarose gel and
analyzed by direct visualization after ethidium bromide
staining. Specificity of the RT-PCR products was assessed
by Southern blot analysis, as previously described [15].
Samples were considered positive when a PCR product
was detected by either direct visualization or blot analysis.
Statistical Analysis
To assess whether the detection of CMC in peripheral
blood samples serially taken from MM patients could
have prognostic value, the following criteria were used.
PCR-based amplification of at least one mRNA marker
(tyrosinase, MelanA/MART1, or both) in a peripheral
blood specimen was considered a signal of the presence of
CMC (referred to as PCR-positive assay). Presence of CMC
was used as a binary (no/yes) explanatory variable.
Univariate associations between PCR-based markers and
clinico-pathological variables [AJCC stage (I to III), Bres-
low thickness of primary tumour [22], Clark level of inva-
sion (I to V) [23], sex, age at diagnosis] were investigated
by chi-square test. The Cox regression model was per-
formed using the raw mortality and the tumour specific
mortality as a censoring. The time of overall survival was
expressed in months. In all statistical analyses, P < 0.05
was considered significant. All analyses were performed
with the statistical package SPSS/7.5 per Windows.
Results
A consecutive cohort of 149 patients with histologically-
proven diagnosis of MM from January 9, 1997 to Decem-
ber 16, 1997 was studied. Patients were prevalently
females, with a median age of 48 years (range 16–85).
According to the new AJCC stage classification, almost the
half of the patients had stage I disease (72; 48%), and one-
third had stage II (49; 33%). Overall, patients without
lymph node metastases (stages I to II) accounted for 81%
of the series (Table 1).
Detection of circulating mRNA markers (tyrosinase,
MelanA/MART1, or both) in a blood sample was consid-
ered a signal of the presence of CMC (referred to as PCR-
positive assay). During the first two years after diagnosis,
peripheral blood samples from MM patients undergoing
follow-up visits every six month (times 6, 12, 18, and 24
months) were screened for CMC by RT-PCR assays. In
Table 2, total number of PCR-positive assays (ranging
from 0, in patients with all five blood samples negative for
mRNA markers, to 5, in patients with all five blood sam-
ples positive for mRNA markers) was compared to the dis-
ease stage. No statistical association between positive RT-
PCR assays and the stage of disease was observed.
As of December 2005, 49 patients (33%) have suffered
progression (site of recurrence: 27 regional lymph nodes,
6 distant lymph nodes, 7 skin (in transit metastases), 6 vis-
ceral sites, 3 brain); 28 patients (19%) have died of
melanoma. For the entire series of 149 patients included
into the study, median follow-up was 83 months (range,
24–93). Four patients recurred after 20 months; blood
drawing at month 24 (sample 5) was anyhow performed
and such patients were not excluded from the study. No
patient in our series died within 24 months from diagno-
sis.
At univariate analysis the presence of PCR-positive assays
had a significant predictive value. As shown in Table 3, we
compared the total number of PCR-positive assays
Table 1: Characteristics of patients
Characteristics Number of patients %
Total analyzed 149
Sex
Males 59 40
Females 90 60
Median Age (years) 48
Range 16–85
AJCC stage
IA 50 33
IB 22 15
IIA 36 24
IIB 12 8
IIC 1 1
III 28 19
Primary site
Head and Neck 13 9
Superior limbs 23 15
Inferior limbs 47 32
Trunk 63 42
Unknown 3 2
Staging was according to the recent American Joint Committee on 
Cancer (AJCC) guidelines. Data refer to the time of diagnosis.BMC Cancer 2006, 6:266 http://www.biomedcentral.com/1471-2407/6/266
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(regardless the timing of the blood sampling) with either
the rate of disease recurrences or the median disease-free
survival (DFS) and the median overall survival (OS). A
significant correlation was found between the rate of
recurrences and the increasing number of PCR-positive
assays [11 (17%) relapses in 64 cases with 0–1 PCR-posi-
tive assay vs. 38/85 (45%) cases with ≥2 PCR-positive
assays (P = 0.007)] (Table 3). While no significant differ-
ence in DFS and OS was observed for MM patients with ≤2
positive RT-PCR assay (median DFS: 81 months; median
OS: 83 months), presence of CMC in ≥3 peripheral blood
samples was significantly correlated with a poor clinical
outcome [median DFS: 73 months (P = 0.019); median
OS: 76 months (P = 0.034)] (Table 3).
Considering the timing of PCR results, a correlation
between the rate of recurrences and the variation of the
CMC status during follow-up was inferred. In Table 4,
patients were classified according to the RT-PCR results
obtained at and after baseline blood drawing. A quite low
relapse rate was observed in patients with all five RT-PCR
assays negative as well as in those who went from positive
in initial assay to negative in remaining assays (altogether,
4/33; 12%) (Table 4). On the other hand, frequency of
relapses were much higher in patients with positive RT-
PCR assays during follow-up, regardless the baseline sta-
tus (altogether, 45/116; 39%) (Table 4).
No statistical correlation between the RT-PCR status and
Breslow thickness, Clark level of invasion, primary site,
sex, or age at diagnosis was observed.
The Cox regression multivariate analysis was performed
on the totality of patients in order to estimate the role of
different disease parameters as well as of the RT-PCR sta-
tus on clinical outcome in terms of overall survival. In
addition to the expected variables represented by the pri-
mary tumor extension (as inferred by the Breslow thick-
ness) (Table 5) or the more reliable and comprehensive
stage of disease (Table 6), the presence of at least two PCR-
positive assays remained a statistically independent prog-
nostic factor for overall survival in patients with malig-
nant melanoma (Tables 5 and 6).
Discussions and Conclusion
In this paper, we showed that presence of circulating
malignant cells (CMCs), assessed through a PCR-based
detection of multiple mRNAs corresponding to
melanoma-associated molecular markers (tyrosinase and
MelanA/MART1), in a high fraction of peripheral blood
samples serially obtained during follow-up visits, does
play a role as independent predictive factor for clinical
outcome.
Taking into consideration both the raw mortality and the
tumour specific mortality as a censoring, survival data
analysis allowed to assess that patients with presence of
melanoma cells in at least two out of the five analyzed
peripheral blood samples (referred to as PCR-positive
assays), collected every six months during the first two
years of follow-up, had a worse clinical outcome with a
significantly shorter overall survival over a median follow-
up of about seven years (83 months). Multivariate analy-
Table 3: Correlation between total number of PCR-positive assays and rates of progression disease or median survivals
No. of positive assays No. of patients No. of PDs (%) median DFS (months) median OS (months)
01 8 3   (17) 81 83
14 6 8   (17) 81 83
2 45 12 (27) 82 83
3 27 17 (63) 78 79
4–5 13 9 (69) 66 70
PD, progression disease; DFS, disease free-survival; OS, overall survival
Table 2: PCR-positive assays in serially-taken peripheral blood samples.
AJCC STAGE (patients) PCR-positive assays No. of PDs (%)
0 (%) 1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
I (72) 6 (8) 30 (42) 22 (31) 9 (12) 4 (6) 1 (1) 12 (17)
IA (50) 3 (6) 21 (42) 15 (30) 7 (14) 3 (6) 1 (2) 8 (16)
IB (22) 3 (14) 9 (41) 7 (32) 2 (9) 1 (4) 0 (0) 4 (18)
II (49) 4 (8) 10 (20) 19 (39) 12 (25) 2 (4) 2 (4) 17 (35)
IIA (36) 2 (5.5) 8 (22) 14 (39) 9 (25) 2 (5.5) 1 (3) 11 (31)
IIB-IIC (13) 2 (15) 2 (15) 5 (39) 3 (23) 0 (0) 1 (8) 6 (46)
III (28) 4 (14) 6 (21) 8 (29) 6 (21) 3 (11) 1 (4) 20 (71)
TOTAL (149) 14 (9) 46 (31) 49 (33) 27 (18) 9 (6) 4 (3) 49 (33)
PD, progression diseaseBMC Cancer 2006, 6:266 http://www.biomedcentral.com/1471-2407/6/266
Page 5 of 8
(page number not for citation purposes)
Table 5: Multivariate analysis for overall survival including primary tumour extension
Marker Hazard Ratio 95% CI P
Sex 1,185 0,49–2.83 0.702
Age 1.108 0.93–1.13 0.390
Breslow thickness 2.530 1.62–3.94 < 0.001
CMC status (0–1 vs ≥2 positive assays) 2.685 1.17–6.49 0.026
CI, confidence interval
Table 4: Correlation between timing of PCR results and rates of progression disease
PCR assay results No. patients No. of PDs (%)
Baseline Follow-up
negative negative 18 3 (17)
negative positive 56 19 (34)
positive negative 15 1 (7)
positive positive 60 26 (43)
PD, progression disease
Table 6: Multivariate analysis for overall survival including disease stage
Marker Hazard Ratio 95% CI P
Sex 1.013 0.46–2.19 0.973
Age 1.011 0.98–1.04 0.480
AJCC Stage (I-III) 2.907 1.24–6.81 0.014
CMC status (0–1 vs ≥2 positive assays) 2.468 1.12–6.23 0.037
CI, confidence intervalBMC Cancer 2006, 6:266 http://www.biomedcentral.com/1471-2407/6/266
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sis revealed that such a high level (≥2) of PCR-positive
assays does correlate with the overall survival in
melanoma patients, thus adding precision to the predic-
tive power of the stage of disease (see Tables 5 and 6).
Nevertheless, increasing number of PCR-positive assays in
serially-taken peripheral blood samples was also found
significantly associated with a higher rate of relapses (see
Table 3). This seems to further suggest that such an
approach could help in defining a high risk subset of
melanoma patients.
A multiple-marker RT-PCR assay has been demonstrated
to be more sensitive and specific than single-marker assay
in detecting circulating melanoma metastases [7,14,15].
Previously, we observed that mRNA expression of tyrosi-
nase and MelanA/MART1 was quite completely undetect-
able in peripheral blood of nonmelanoma controls [15],
confirming that these two markers possess the highest
specificity and reliability in detection of melanoma micro-
metastases. In addition, existence of a statistically signifi-
cant association between disease stage and presence of
such tumour-associated mRNAs in peripheral blood as
expression of CMCs has been widely demonstrated
[14,15,19,24]. However, clinical significance and prog-
nostic role of circulating mRNA markers is highly debated
and not completely understood [2,11-19].
Mobilization of cancer cells from the site of the primary
lesion and physical invasion of blood stream are among
the earliest events of tumour progression, necessary,
although not sufficient, to produce distant metastases
[25]. Indeed, colonization of distant tissues and develop-
ment of metastasis represent the result of a multi-step cas-
cade of events occurring to cancer cells during tumour
dissemination (i.e., viability in circulation, capability of
exiting blood stream and starting tissue invasion, presence
of adequate growth potential for metastasis formation)
[26]. Detection of circulating melanoma cells could rea-
sonably correspond to the identification of an early
potential step of metastatic dissemination.
Majority of the published studies in which a multivariate
analysis has been performed reported the strongest corre-
lation of PCR-detected CMCs with the disease stage at the
time of diagnosis, rather than as an independent prognos-
tic factor [13,15,24,27-30]. Among them, studies with
positive conclusions mostly reported very low rates of
events for analysis (quite all investigations were focused
on progression-free survival, which cannot completely
substitute the value of overall survival analysis) [28-30].
Longer follow-up are thus required in order to observe a
higher number of such events (with particular attention to
the melanoma-related deaths for accurate calculation of
the overall survival [31]), in order to infer a more appro-
priate evaluation of the clinical role of RT-PCR assays.
Considering such a correlation between presence of CMCs
at the time of diagnosis and the initial stage of disease,
one could speculate that detection of CMCs may represent
a surrogate for clinical staging. However, our group has
previously demonstrated that detection of melanoma-
associated transcripts in peripheral blood of melanoma
patients at the time of diagnosis by RT-PCR, when
adjusted by disease stage, had no significant predictive
value for clinical outcome [19]. Stage of disease remained
the only prognostic factor known to correlate with time to
recurrence and/or overall survival [19,21].
The results of the present study further suggest that meta-
static cancer cells might be constantly present in blood cir-
culation of a subset of melanoma patients, before the
establishment of distant metastases. In this light, pro-
longed presence of melanoma cells in blood stream may
indeed represent either a surrogate marker of disease pro-
gression or a sign of more aggressive disease, due to selec-
tion of viable cancer cells with better capacity to invade
the target tissue and higher growth potential at the distant
site (see Table 4). Supporting this hypothesis, another
study defined the existence of changes in CMCs during
interferon therapy among MM patients with more
advanced disease (stages II-IV) [32]. Using multivariate
analysis, these Authors demonstrated that patients who
became CMC-negative during interferon therapy were sig-
nificantly associated with better disease-free survival than
those who remained or became positive during therapy
[32]. In addition to the stage of disease as the most impor-
tant prognostic factor, change in CMC status during a pro-
longed observation period may be indeed of prognostic
value.
Dynamic studies, such as the present one, aimed to assess
any modification of the circulating malignant cell status
by RT-PCR assay throughout follow-up or treatment
deserves further prospective investigations among
patients with melanoma. A more extensive application of
the real-time quantitative RT-PCR approach [33,34] may
further improve the specificity of standard qualitative RT-
PCR assays. This may help in establishing a detection
threshold above which sensitivity for clinically significant
micrometastases can be optimized and false-positives can
be minimized.
Although more accurate approaches for detection and
characterization of circulating melanoma are under evalu-
ation, the results of our analysis strongly indicate that any
future study evaluating molecular status will necessitate
suitable long-term median follow-up (at least five years)
to provide clinically relevant information and define out-BMC Cancer 2006, 6:266 http://www.biomedcentral.com/1471-2407/6/266
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come for patients with occult melanoma metastases. Pre-
diction of metastatic potential remains one of the main
goals to be pursued in order to better assess the risk sub-
groups of patients with malignant melanoma.
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